• Explore /
  • Poster
  • / Dose escalation and expansion from the phase I study of DS-1062, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients (pts) with advanced non-small cell lung cancer (NSCLC).

Dose escalation and expansion from the phase I study of DS-1062, a trophoblast cell-surface antigen 2 (TROP2) antibody drug conjugate (ADC), in patients (pts) with advanced non-small cell lung cancer (NSCLC).

Abstract Poster

Authors

null

Aaron Elliott Lisberg

Department of Medicine, Division of Hematology/Oncology, UCLA, Los Angeles, CA

Aaron Elliott Lisberg , Jacob Sands , Toshio Shimizu , Jonathan Greenberg , Penny Phillips , Ferdinand M. Guevara , Yutaka Noguchi , Tadashi Toki , Alexander I. Spira , Noboru Yamamoto , Melissa L. Johnson , Funda Meric-Bernstam , Kiyotaka Yoh , Edward B. Garon , Rebecca Suk Heist

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT03401385

Citation

J Clin Oncol 38: 2020 (suppl; abstr 9619)

DOI

10.1200/JCO.2020.38.15_suppl.9619

Abstract #

9619

Poster Bd #

385

Abstract Disclosures

Similar Posters

First Author: Jing Huang

First Author: Anas Gazzah

First Author: Mohamed Shanshal

First Author: Gottfried E. Konecny